# An Open Label Phase 2 Study of Total Neoadjuvant Therapy (TNT) Consisting of FLOT With Pembrolizumab and Short Radiation for Patients With Locally Advanced Gastroesophageal Junction Adenocarcinoma

> **NCT07018570** · PHASE2 · RECRUITING · sponsor: **National Cancer Center Hospital East** · enrollment: 26 (estimated)

## Conditions studied

- Gastroesophageal Junction (GEJ) Adenocarcinoma

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Docetaxel
- **DRUG:** Oxaliplatin
- **DRUG:** Levofolinate
- **DRUG:** Fluorouracil (5-FU)
- **RADIATION:** Radiation Therapy

## Key facts

- **NCT ID:** NCT07018570
- **Lead sponsor:** National Cancer Center Hospital East
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-24
- **Primary completion:** 2030-06
- **Final completion:** 2031-06
- **Target enrollment:** 26 (ESTIMATED)
- **Last updated:** 2025-08-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07018570

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07018570, "An Open Label Phase 2 Study of Total Neoadjuvant Therapy (TNT) Consisting of FLOT With Pembrolizumab and Short Radiation for Patients With Locally Advanced Gastroesophageal Junction Adenocarcinoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07018570. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*